| Date | Form | Description | Docs | XBRL | Pages |
| 01/29/96 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
44 | |
| 09/12/95 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
16 | |
| 09/06/95 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
15 | |
| 09/06/95 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 | |
| 06/30/95 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
8 | |
| 06/27/95 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 06/14/95 | DEF 14A | Definitive proxy statements |
|
15 | |
| 06/09/95 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
16 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...